Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Biogen Inc. (BIIB) reported $2.65 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 7.3%. EPS of $5.47 for the same period compares to $5.28 a year ago.The reported revenue represents a surprise of +13.89% over the Zacks Consensus Estimate of $2.32 billion. With the consensus EPS estimate being $3.93, the EPS surprise was +39.19%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Biogen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Revenue- Product- Rare Disease- SKYCLARYS - United States: $78 million compared to the $75.44 million average estimate based on 23 analysts.Revenue- Product- Multiple Sclerosis (MS)- TYSABRI- Rest of world: $182.4 million versus the 23-analyst average estimate of $171.91 million. The reported number represents a year-over-year change of -14.6%.Revenue- Product- Rare Disease- SKYCLARYS - Rest of World: $52.3 million versus $53.63 million estimated by 23 analysts on average.Revenue- Product- Multiple Sclerosis (MS)- TYSABRI- United States: $272.2 million versus $203.91 million estimated by 23 analysts on average. Compared to the year-ago quarter, this number represents a +9.5% change.Revenue- Product- Multiple Sclerosis (MS)- TYSABRI- Total: $454.6 million versus $372.66 million estimated by 27 analysts on average. Compared to the year-ago quarter, this number represents a -1.6% change.Revenue- Product- Rare Disease- SPINRAZA- Total: $392.7 million versus $396.92 million estimated by 27 analysts on average. Compared to the year-ago quarter, this number represents a -8.5% change.Revenue- Product- Rare Disease- SKYCLARYS- Total: $130.3 million versus the 26-analyst average estimate of $128.37 million. The reported number represents a year-over-year change of +30.3%.Revenue- Product, net: $1.88 billion compared to the $1.72 billion average estimate based on 26 analysts. The reported number represents a change of -1.1% year over year.Revenue- Anti-CD20 therapeutic programs: $467.3 million compared to the $431.19 million average estimate based on 26 analysts. The reported number represents a change of +5.1% year over year.Revenue- Product- Multiple Sclerosis (MS)- Fumarate- VUMERITY- Total: $212.3 million versus the 25-analyst average estimate of $170.04 million. The reported number represents a year-over-year change of +28.1%.Revenue- Product- Multiple Sclerosis (MS)- Fumarate- TECFIDERA- Total: $193.6 million versus $178.41 million estimated by 25 analysts on average. Compared to the year-ago quarter, this number represents a -23.2% change.Revenue- Product- Other- ZURZUVAE- Total: $46.4 million versus $32.61 million estimated by 24 analysts on average.View all Key Company Metrics for Biogen here>>>Shares of Biogen have returned -4.9% over the past month versus the Zacks S&P 500 composite's +2.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.One Big Gain, Every Trading DayTo help you take full advantage of this market, you’re invited to access every stock recommendation in all our private portfolios - for just $1.Zacks private portfolio services that closed 256 double and triple-digit winners in 2024 alone. That’s about one big gain every day the market was open. Of course, not all our picks are winners, but members have seen recent gains as high as +627% +1,340%, and +1,708%.Imagine how much you could profit with a steady stream of real-time picks from all our services that cover a number of strategies to suit a variety of investing and trading styles.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Biogen Inc. (BIIB): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks